Zobrazeno 1 - 10
of 189
pro vyhledávání: '"Nicole M. Kuderer"'
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-4 (2022)
Externí odkaz:
https://doaj.org/article/fc3a7992752645b0a4219b489965a012
Autor:
Despina Michailidou, Tianyu Zhang, Nicole M. Kuderer, Gary H. Lyman, Andreas P. Diamantopoulos, Pavlos Stamatis, Bernard Ng
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Giant cell arteritis (GCA) that affects older patients is an independent risk factor for thromboembolic events. The objective of this study was to identify predictive factors for thromboembolic events in patients with GCA and develop quantitative pre
Externí odkaz:
https://doaj.org/article/a1dee889ff1c4d31aae77c5268ebffd7
Autor:
Alok A. Khorana, Nicole M. Kuderer, Keith McCrae, Dejan Milentijevic, Guillaume Germain, François Laliberté, Sean D. MacKnight, Patrick Lefebvre, Gary H. Lyman, Michael B. Streiff
Publikováno v:
Cancer Medicine, Vol 9, Iss 21, Pp 8062-8073 (2020)
Abstract Background The Khorana score (KS) clinical algorithm is used to predict VTE risk in cancer patients. The study objective was to evaluate VTE and survival rates among patients newly diagnosed with cancer and stratified by KS in a real‐world
Externí odkaz:
https://doaj.org/article/6e3e3acb042d48c0b6344f8f70c12a5f
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HPSCs) often results in myelosuppression that adversely affects patient health and quality of life. Currently, chemotherapy-induced myelosuppression is managed with chemotherapy
Externí odkaz:
https://doaj.org/article/57b7357bb52c4c438749d10bbd35e9e6
Autor:
Nigel S. Key, Alok A. Khorana, Nicole M. Kuderer, Kari Bohlke, Agnes Y.Y. Lee, Juan I. Arcelus, Sandra L. Wong, Edward P. Balaban, Christopher R. Flowers, Leigh E. Gates, Ajay K. Kakkar, Margaret A. Tempero, Shilpi Gupta, Gary H. Lyman, Anna Falanga
Publikováno v:
Journal of Clinical Oncology. 41:3063-3071
PURPOSE To conduct an update of the ASCO venous thromboembolism (VTE) guideline. METHODS After publication of potentially practice-changing clinical trials, identified through ASCO's signals approach to updating, an updated systematic review was perf
Autor:
Marco Tagliamento, Alessandra Gennari, Matteo Lambertini, Ramon Salazar, Nadia Harbeck, Lucia Del Mastro, Juan Aguilar-Company, Mark Bower, Rachel Sharkey, Alessia Dalla Pria, Andrea Plaja, Amanda Jackson, Jasmine Handford, Ailsa Sita-Lumsden, Clara Martinez-Vila, Marta Matas, Ana Miguel Rodriguez, Bruno Vincenzi, Giuseppe Tonini, Alexia Bertuzzi, Joan Brunet, Paolo Pedrazzoli, Francesca D'Avanzo, Federica Biello, Alasdair Sinclair, Alvin J.X. Lee, Sabrina Rossi, Gianpiero Rizzo, Oriol Mirallas, Isabel Pimentel, Maria Iglesias, Ana Sanchez de Torre, Annalisa Guida, Rossana Berardi, Alberto Zambelli, Carlo Tondini, Marco Filetti, Francesca Mazzoni, Uma Mukherjee, Nikolaos Diamantis, Alessandro Parisi, Avinash Aujayeb, Aleix Prat, Michela Libertini, Salvatore Grisanti, Maura Rossi, Federica Zoratto, Daniele Generali, Cristina Saura, Gary H. Lyman, Nicole M. Kuderer, David J. Pinato, Alessio Cortellini
Publikováno v:
Journal of Clinical Oncology. 41:2800-2814
PURPOSE Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active cancer therapy included in vaccinat
Publikováno v:
Cancer Investigation. 41:1-11
Reliable risk models can greatly facilitate patient-centered inferences and decisions. Herein we summarize key considerations related to risk modeling in clinical oncology. Often overlooked challenges include data quality, missing data, effective sam
Publikováno v:
Nature Reviews Clinical Oncology.
Publikováno v:
Nature Reviews Clinical Oncology. 19:681-697
Autor:
Fabrice Andre, Nofisat Ismaila, Kimberly H. Allison, William E. Barlow, Deborah E. Collyar, Senthil Damodaran, N. Lynn Henry, Komal Jhaveri, Kevin Kalinsky, Nicole M. Kuderer, Anya Litvak, Erica L. Mayer, Lajos Pusztai, Rachel Raab, Antonio C. Wolff, Vered Stearns
Publikováno v:
Journal of Clinical Oncology. 40:1816-1837
PURPOSE To update recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer. METHODS An updated literature search identified randomized clinical tri